Intravenous Immunoglobulin Market Size is estimated to grow at a CAGR of 7.0% during the forecast period
During the projected period of 2022–2030, the global intravenous immunoglobulin market is
anticipated to expand at a compound annual growth rate (CAGR) of 7.0%.
Intravenous immunoglobulin (IVIG) is a blood product or
therapy used to treat a variety of illnesses, such as immune thrombocytopenic
purpura, hypogammaglobulinemia, Kawasaki disease, Guillain-Barré syndrome,
primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy,
some cases of HIV/AIDS and measles, and various other infectious diseases. It
can be injected into a vein, a muscle, or beneath the skin, depending on how it
is made. IVIg is useful for maintaining the proper level of antibodies in the
bodies of people or patients who are unable to manufacture enough antibodies.
Request
For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/intravenous-immunoglobulin-Market
Growth Drivers:
The burgeoning adoption and demand of novel intravenous
immunoglobulins for the treatment of various diseases, the rising number of
hemophiliac patients, improving technologies for the production of
immunoglobulin and improved purification techniques, the rising demand for more
effective and adequate treatment measures, and the soaring investments in the healthcare
sector worldwide are the main factors driving the growth of this market.
Additionally, the number of innovations and brand-new
product introductions in the intravenous immunoglobulin market is rapidly
growing. This also includes the introduction of numerous complementary
therapies that raise awareness of immunoglobulin. The European Medicine Agency
(EMA), the Food and Drug Administration (FDA), and other governmental
organizations are also increasingly approving different IVIG medications, creating
new growth and revenue potential for the market participants operating in the
global intravenous immunoglobulin market.
However, during the forecast period, factors like the
strict regulatory approval procedures and guidelines toward the widespread use
of intravenous immunoglobulin products, the high cost of therapy, and the
possibility of side effects associated with intravenous immunoglobulin products
are expected to restrain the growth of the global intravenous immunoglobulin market.
Intravenous Immunoglobulin Market
Segmentation:
By Type:
· IgG
· IgA
· IgM
· IgE
· IgD
By Application:
· Hypogammaglobulinemia
· Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP)
· Immunodeficiency
Disease
· Myasthenia
Gravis
· Multifocal
Motor Neuropathy
· Idiopathic
Thrombocytopenic Purpura (ITP)
· Inflammatory
Myopathies
· Specific
Antibody Deficiency
· Guillain–Barré
Syndrome
· Others
By Region:
· North
America
· Europe
· Asia
Pacific
· Latin
America
· Middle
East and Africa
Key Companies in Intravenous Immunoglobulin
Market:
· Kedrion
Biopharma Inc.
· LFB
group
· Biotest
AG
· China
Biologics Products Inc.
· Bayer
Healthcare
· Baxter
international Inc.
· CSL
Ltd.
· Grifols
S.A
· Octapharma
AG
· Takeda
Pharmaceutical Company Limited
· Bio
Products Laboratory Limited
· Other
Players
For
More Information about this Report @ https://www.xresearch.biz/shop/intravenous-immunoglobulin-Market
About
Us:-
xResearch is a market research and consulting
organization that uses unique data, expert analysis, and new technologies to
create trusted intelligence on industries. Our research is focused on
delivering an informed and impartial view on essential market data of industry,
and it is primarily driven by an in-depth study covering the following
parameters: Market Sizing and Forecasting, Market Segmentation, Competitive
Analysis, Strategic Assessment and Business Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-618-4545
Comments
Post a Comment